계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
AVM Biotechnology
company
About
AVM Biotechnology is a clinical stage company.
- 11 - 50
Highlights
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $2M
- Industries
- Biotechnology,Medical,Pharmaceutical
- Founded date
- Jan 1, 2008
- Number Of Employee
- 11 - 50
- Operating Status
- Active
AVM is a clinical-stage biotech company located in Seattle WA led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and 4 discoveries in clinical trials. The company's lead drug AVM0703, an innovative formulation of dexamethasone, when given at suprapharmacologic doses has a novel mechanism of action to mobilize the body's own natural supercharged immune cells. AVM0703 could be the first choice for no-option cancer, autoimmunity, and infectious disease. AVM Biotechnology has a Scientific Advisory Board including well-respected leaders in cancer and immunology.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$2M
AVM Biotechnology has raised a total of
$2M
in funding over 2 rounds. Their latest funding was raised on
Jun 14, 2022 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 14, 2022 | Grant | $2M | 1 |
National Institutes of Health
|
— | Detail |
| Jun 11, 2020 | Grant | — | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
AVM Biotechnology is funded by 2 investors.
National Institutes of Health
and National Institutes of Health (NIH)
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
|
|
— | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
